Incretin‐based T2DM therapies, including GLP‐1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are generally well tolerated and have been used for many years to regulate glucose metabolism and manage T2DM in humans.8, 9. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.